The Boston Company

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in acquiring and developing high-potential drug candidates from early-stage development through proof-of-concept. Founded by Gurnet Point Capital and led by industry veterans, the company employs a unique business model of in-licensing assets from major pharmaceutical companies like GSK and Novartis to accelerate their clinical progression. Its lead program, efimosfermin alfa (BOS-580), is a long-acting FGF21 analog being evaluated in Phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company maintains a diverse pipeline across multiple therapeutic areas, including hepatology, oncology, and immunology, with a focus on addressing significant unmet medical needs.